

# Truenat<sup>®</sup> M.leprae

Chip-based Real-Time PCR Test  
for *Mycobacterium leprae*



# Leprosy: Eliminated, Not Eradicated

## Challenge

Limitations of conventional tools like microscopy and clinical assessment, especially in early-stage and paucibacillary (PB) leprosy, hinder timely detection.

## Result

Prolonged transmission, irreversible nerve damage, and continued social stigma and discrimination.

Early community-level detection is both a clinical and ethical imperative to stop transmission and end this enduring threat.

## GLOBAL STATISTICS

Despite being declared an eliminated disease in 2000, leprosy continues to impact over —



**800,000**

people each year.



**1,82,815**

New cases reported in 2023.

Over

**95%**

occurred in just 23 countries, including India, Indonesia, DRC, and Brazil.



**Nearly  
120 countries  
still report  
new cases  
annually**



## Bridging the Diagnostic Gap: The WHO Perspective


Leprosy is diagnosed when at least one of these cardinal signs is present:



Hypopigmented skin lesions with definite loss of sensation



Peripheral nerve involvement



Presence of acid-fast bacilli in slit-skin smears

Traditional methods fall short in early or indeterminate cases. Slit-skin smears, ELISA, and lateral flow assays show low sensitivity—especially for paucibacillary (PB) cases.


Recognising this, WHO endorses nucleic acid amplification tests (NAATs), including PCR-based tools, for their superior sensitivity and specificity.

(\*WHO Factsheet 2025)

## Molecular Precision, Point-of-Care Simplicity

Truenat M. leprae is a real-time PCR test developed for the early and accurate detection of *Mycobacterium leprae* DNA—even in low-burden PB cases.

Running on the WHO-endorsed Truenat® platform, it delivers lab-grade accuracy in field settings.



By enabling rapid, onsite diagnosis, it supports the Global Leprosy Strategy 2021–2030:

**Zero  
Transmission.**

**Zero  
Disability.**

**Zero  
Discrimination.**

# KEY FEATURES



## User-friendly

Requires minimal human resource training



## Multiplex RT-PCR for dual-target detection



## <1 hour turnaround time



## Lyophilized, ready-to-use PCR reagents



## Smart chip

Replete with batch-specific data



## Minimal biosafety requirements

Can be used even in resource limited settings



## Long shelf life

Storage at room temperature



## Contamination/evaporation-resistant design

To provide maximum control

## ORDERING INFORMATION

Pack Size	5T	20T	25T	50T
Cat. No.	601700005	601700020	601700025	601700050



**MOLBIO DIAGNOSTICS LIMITED**  
L-46, Phase II D, Verna Industrial Estate,  
Verna, Goa - 403 722, India



+91 832-2783267



[sales@molbiodiagnostics.com](mailto:sales@molbiodiagnostics.com)



[www.molbiodiagnostics.com](http://www.molbiodiagnostics.com)



[customersupport@molbiodiagnostics.com](mailto:customersupport@molbiodiagnostics.com)